Skip to content

10X Genomics Inc Price, Chart & Factor Exposure

Free Data & Analytics Access
10X Genomics Inc · E.TXG.NASDAQ · United States
Use symbol E.TXG.NASDAQ in our API & Excel add-in to retrieve this data ↓
81.55
(-0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 0%
Trend 75%
Bubble Risk LOW
Realised Volatility (20D) 96.62%

10X Genomics Inc Forecast

10X Genomics Inc short-term momentum is neutral (up over 2 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term NEUTRAL signal. The long-term trend is strongly positive (7 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 96.6% a year, a typical one-standard-deviation range is 70.45–92.65 over a week, 58.80–104.30 over a month and 2.7538–160.35 over a year. (Signals as of 1 Nov 2026.)

10X Genomics Inc Price Chart

MacroFinance.ai

10X Genomics Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
10X Genomics Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
10X Genomics Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
10X Genomics Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
10X Genomics Inc
P/S
17.24x
Stretched vs own history
QoQ +25.7%
YoY +380.9%
now 17.24483.02 low19.7 high
ⓘP/S As of 22 Nov 2026.See 10X Genomics Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
10X Genomics Inc
P/B
12.73x
Stretched vs own history
QoQ +24.1%
YoY +334.2%
now 12.72882.47 low14.72 high
ⓘP/B As of 22 Nov 2026.See 10X Genomics Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
10X Genomics Inc
EV/EBITDA
227.73x
Mid-range vs own history
QoQ +7.3%
YoY —
now 227.726924.24 low310.09 high
ⓘEV/EBITDA As of 22 Nov 2026.See 10X Genomics Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
10X Genomics Inc
EV/Sales
16.44x
Stretched vs own history
QoQ +26.9%
YoY +432.0%
now 16.43672.53 low18.93 high
ⓘEV/Sales As of 22 Nov 2026.See 10X Genomics Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
10X Genomics Inc
FCF Yield
0.9%
Mid-range vs own history
QoQ −38.7%
YoY −75.2%
now 0.87910.88 low5.65 high
ⓘFCF Yield As of 22 Nov 2026.See 10X Genomics Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
10X Genomics Inc
Earnings Yield
-0.6%
Strong vs own history
QoQ −29.2%
YoY −81.0%
now -0.6288-3.93 low-0.37 high
ⓘEarnings Yield As of 22 Nov 2026.See 10X Genomics Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
10X Genomics Inc
Market Cap
$10.7B
Highest in 5 years
QoQ +26.0%
YoY +363.4%
now 10667.2131,940 low12,154 high
ⓘMarket Cap As of 22 Nov 2026.See 10X Genomics Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
10X Genomics Inc
Net Debt
-$500M
Low vs own history
QoQ +5.6%
YoY +56.9%
now -499.888-499.89 low-318.66 high
ⓘNet Debt As of 22 Nov 2026.See 10X Genomics Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
10X Genomics Inc
Net Debt / EBITDA
-11.20x
-11.20x
QoQ −10.9%
YoY —
now -11.1965-12.56 low-4.91 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See 10X Genomics Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
10X Genomics Inc
Current Ratio
5.12x
Mid-range vs own history
QoQ −10.1%
YoY +14.3%
now 5.11954.46 low5.9 high
ⓘCurrent Ratio As of 22 Nov 2026.See 10X Genomics Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
10X Genomics Inc
Quick Ratio
4.66x
Mid-range vs own history
QoQ −11.2%
YoY +14.8%
now 4.65914.06 low5.42 high
ⓘQuick Ratio As of 22 Nov 2026.See 10X Genomics Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
10X Genomics Inc
Debt / Equity
0.09x
Low vs own history
QoQ −5.3%
YoY −56.6%
now 0.09040.09 low0.21 high
ⓘDebt / Equity As of 22 Nov 2026.See 10X Genomics Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
10X Genomics Inc
Piotroski F-Score
6
Mid-range vs own history
QoQ +20.0%
YoY +50.0%
now 64 low6 high
ⓘPiotroski F-Score As of 22 Nov 2026.See 10X Genomics Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
10X Genomics Inc
Altman Z-Score
27.62
Strong vs own history
QoQ +15.3%
YoY +493.5%
now 27.61713.76 low34.78 high
ⓘAltman Z-Score As of 22 Nov 2026.See 10X Genomics Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  19 members-only factors: Sloan Accruals, Cash-Earnings Gap, Days Sales in Receivables Index, Gross Margin Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for 10X Genomics Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

10X Genomics Inc fundamentals: income statement, balance sheet & cash flow

10X Genomics Inc reported revenue of $642.8m and net income of -$43.5m in FY2025, the year ended 31 December 2025 — revenue up 5.2% and net income up 76.2% on the prior year. Free cash flow was $130.1m. These figures are as reported in the filings, not restated: 9 fiscal years and 35 quarters of history, back to December 2017. 166 FINRA short-interest settlements are published alongside them, back to September 2019.

Revenue (FY2025)
$642.8m
+5.2%
Net income
-$43.5m
+76.2%
Gross margin
69.05%
Free cash flow
$130.1m
+2,371.2%
Net debt
-$316.2m
Shares short (30 Oct 2026)
12.47m
4.13 days to cover
10X Genomics Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue642.8610.8618.7516.4490.5
Cost of revenue198.9196.3209.4120.474.1
Gross profit443.9414.5409.3396.0416.4
Research & development238.6264.7270.3265.7211.8
Selling, general & admin.316.1————
Operating income-110.9-194.6-265.3-167.9-52.9
EBITDA3.9-134.0-205.1-128.5-24.6
Interest expense0.00.00.00.50.9
Pre-tax income-39.9-177.7-248.8-162.0-53.7
Income tax3.64.96.34.04.5
Net income-43.5-182.6-255.1-166.0-58.2

Download 10X Genomics Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.TXG.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks the full history, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on 10X Genomics Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

10X Genomics Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to 10X Genomics Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How 10X Genomics Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how 10X Genomics Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About 10X Genomics Inc (United States)

10X Genomics Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on 10X Genomics Inc

Frequently asked questions

What is 10X Genomics Inc?
10X Genomics Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest 10X Genomics Inc price?
The latest close is 81.55 (1 Nov 2026), -0.02% on the day. The price at the top of the page refreshes during the trading day.
Is 10X Genomics Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is neutral (2 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (7 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is 10X Genomics Inc?
20-day realised volatility is 96.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 27.9% over a month and 13.6% over a week.
What factors affect 10X Genomics Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to 10X Genomics Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade 10X Genomics Inc?
58 backtested tactical asset allocation strategies trade 10X Genomics Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are 10X Genomics Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of 10X Genomics Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free 10X Genomics Inc historical data?
In the Free historical data section of this page: the last 10 years of 10X Genomics Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free 10X Genomics Inc historical data (last 10 years)

Browse or instantly download the last 10 years of 10X Genomics Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.TXG.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2051.8
2026-11-1957.38
2026-11-1857.07
2026-11-1756.3
2026-11-1654.99
2026-11-1358.19
2026-11-1259.1
2026-11-1162.05
2026-11-1062.9
2026-11-0965.05
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.